Department of Genetics, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.
Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.
Front Immunol. 2021 Dec 7;12:734763. doi: 10.3389/fimmu.2021.734763. eCollection 2021.
BACKGROUND & AIMS: Celiac disease (CeD), an immune-mediated disease with enteropathy triggered by gluten, affects ~1% of the general European population. Currently, there are no biomarkers to predict CeD development. MicroRNAs (miRNAs) are short RNAs involved in post-transcriptional gene regulation, and certain disease- and stage-specific miRNA profiles have been found previously. We aimed to investigate whether circulating miRNAs can predict the development of CeD.
Using next-generation miRNA-sequencing, we determined miRNAs in >200 serum samples from 53 participants of the PreventCD study, of whom 33 developed CeD during follow-up. Following study inclusion at 3 months of age, samples were drawn at predefined ages, diagnosis (first anti-transglutaminase antibody (TGA) positivity or diagnostic biopsy) and after the start of a gluten-free diet (GFD). This allowed identification of circulating miRNAs that are deregulated before TGA positivity. For validation of the biomarkers for CeD and GFD response, two additional cohorts were included in subsequent meta-analyses. Additionally, miRNAs were measured in duodenal biopsies in a case-control cohort.
53 circulating miRNAs were increased (27) or decreased (26) in CeD controls. We assessed specific trends in these individual miRNAs in the PreventCD cohort by grouping the pre-diagnostic samples of the CeD patients (all had negative TGA) by how close to seroconversion (first sample positive TGA) the samples were taken. 8/53 miRNAs differed significantly between controls and samples taken <1 year before TGA positivity: miR-21-3p, miR-374a-5p, 144-3p, miR-500a-3p, miR-486-3p let-7d-3p, let-7e-5p and miR-3605-3p. 6/26 downregulated miRNAs reconstituted upon GFD, including miR-150-5p/-3p, whereas no upregulated miRNAs were downregulated upon GFD. 15/53 biomarker candidates also differed between CeD biopsies and controls, with a concordant direction, indicating that these circulating miRNAs might originate from the intestine.
We identified 53 circulating miRNAs that are potential early biomarkers for CeD, of which several can be detected more than a year before TGA positivity and some start to normalize upon GFD.
乳糜泻(CeD)是一种由麸质引发的肠病的免疫介导疾病,影响欧洲普通人群的 1%左右。目前,尚无预测 CeD 发展的生物标志物。微小 RNA(miRNA)是参与转录后基因调控的短 RNA,先前已经发现了某些疾病和阶段特异性的 miRNA 谱。我们旨在研究循环 miRNA 是否可以预测 CeD 的发展。
使用下一代 miRNA 测序,我们确定了来自 PreventCD 研究的 53 名参与者的 >200 份血清样本中的 miRNA,其中 33 名参与者在随访期间发展为 CeD。在 3 个月时纳入研究后,按照预定年龄、诊断(首次抗转谷氨酰胺酶抗体(TGA)阳性或诊断性活检)和开始无麸质饮食(GFD)后采集样本。这使得我们能够确定在 TGA 阳性之前失调的循环 miRNA。为了验证 CeD 和 GFD 反应的生物标志物,我们在随后的荟萃分析中纳入了另外两个队列。此外,我们在病例对照队列中测量了十二指肠活检中的 miRNA。
CeD 对照组中 53 个循环 miRNA 升高(27 个)或降低(26 个)。我们通过将 CeD 患者的预诊断样本(所有 TGA 均为阴性)按距离 TGA 阳性的时间分组,评估了这些单个 miRNA 在 PreventCD 队列中的特定趋势:miR-21-3p、miR-374a-5p、144-3p、miR-500a-3p、miR-486-3p、let-7d-3p、let-7e-5p 和 miR-3605-3p。在 TGA 阳性前<1 年采集的样本中,有 8/53 个 miRNA 在对照组和样本之间差异显著:miR-21-3p、miR-374a-5p、144-3p、miR-500a-3p、miR-486-3p、let-7d-3p、let-7e-5p 和 miR-3605-3p。在 GFD 后,26 个下调的 miRNA 中有 6 个重新构成,包括 miR-150-5p/-3p,而在 GFD 后没有上调的 miRNA 下调。在 CeD 活检和对照组之间,53 个候选生物标志物中有 15 个也存在差异,且方向一致,表明这些循环 miRNA 可能源自肠道。
我们鉴定了 53 个循环 miRNA,它们可能是 CeD 的潜在早期生物标志物,其中一些可以在 TGA 阳性前检测到 1 年以上,并且一些在 GFD 后开始正常化。